NEW YORK, NY / ACCESSWIRE / February 23, 2017 / The Pawar Law Group announces a class action lawsuit on behalf of Agile Therapeutics, Inc. ("Agile" or the "Company") (NASDAQ: AGRX) investors who purchased Agile between March 9, 2016 and January 3, 2017, inclusive (the "Class Period"). The suit is for recovery of investor losses.

To participate in this class action lawsuit, visit the firm's website at http://pawarlawgroup.com/cases/agile-therapeutics-inc/ or email Vik Pawar, Esq. at vik@pawarlawgroup.com or call toll free at (866) 999-0873.

No class has been certified in the above action yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the lawsuit, throughout the Class Period defendants issued materially false and misleading statements to investors and/or failed to disclose that: (1) the Twirla contraceptive patch had an efficacy rating that fell below peer group standards; (2) over half of patients in its "Secure" Phase 3 Study discontinued the study early; (3) the Twirla patch therefore allegedly had a slight chance of FDA approval; and (4) as a result, defendants' positive statements about Agile Therapeutics' business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you wish to serve as lead plaintiff, you must move the Court no later than March 7, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You may join the case here: http://pawarlawgroup.com/cases/agile-therapeutics-inc/ or email Vik Pawar, Esq. at vik@pawarlawgroup.com

-------------------------------

Contact:

Vik Pawar, Esq.
Pawar Law Group
20 Vesey Street, Suite 1210
New York, NY 10007
Tel: (212) 571-0805
Fax: (212) 571-0938
vik@pawarlawgroup.com

SOURCE: Pawar Law Group